Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Operating Expenses (2022 - 2025)

Historic Operating Expenses for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $53.7 million.

  • Stoke Therapeutics' Operating Expenses rose 5394.73% to $53.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $178.4 million, marking a year-over-year increase of 3311.55%. This contributed to the annual value of $137.9 million for FY2024, which is 1163.39% up from last year.
  • Per Stoke Therapeutics' latest filing, its Operating Expenses stood at $53.7 million for Q3 2025, which was up 5394.73% from $41.1 million recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Operating Expenses peaked at $53.7 million during Q3 2025, and registered a low of $27.8 million during Q1 2022.
  • For the 4-year period, Stoke Therapeutics' Operating Expenses averaged around $34.7 million, with its median value being $32.4 million (2023).
  • Per our database at Business Quant, Stoke Therapeutics' Operating Expenses skyrocketed by 162.71% in 2023 and then skyrocketed by 5394.73% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Operating Expenses (Quarter) stood at $30.4 million in 2022, then rose by 6.39% to $32.4 million in 2023, then rose by 11.98% to $36.3 million in 2024, then skyrocketed by 48.13% to $53.7 million in 2025.
  • Its Operating Expenses was $53.7 million in Q3 2025, compared to $41.1 million in Q2 2025 and $47.3 million in Q1 2025.